Papaverine hydrochloride: Its questionable value as a vasodilating agent for use in the treatment of peripheral vascular diseases

Abstract

The effectiveness of papaverine hydrochloride intravenously as a vasodilator was studied in a series of eighteen subjects, which included thirteen who suffered from thromboangiitis obliterans, three who had arteriosclerosis obliterans, and two normals. Four patients with Raynaud's syndrome were also observed, but are not included in the statistical analysis. Compared with the simple water immersion procedure for securing vasodilatation, papaverine hydrochloride is ineffective and uncertain in action.